# Roger J Packer

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 304 papers | 24,663 citations | 88 h-index | 150 g-index |
| 325 ext. papers | 28,334 ext. citations | 4.9 avg, IF | 6.51 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 304 | Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. *Journal of Clinical Oncology*, **2006**, 24, 4202-8 | 2.2 | 660 |
| 303 | Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. *Journal of Clinical Oncology*, **1999**, 17, 832-45 | 2.2 | 574 |
| 302 | Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity. *Journal of Neurosurgery*, **1996**, 85, 56-65 | 3.2 | 568 |
| 301 | Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project. *Medical and Pediatric Oncology*, **2002**, 38, 229-39 | | 563 |
| 300 | Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study. *Journal of Clinical Oncology*, **1999**, 17, 2127-36 | 2.2 | 479 |
| 299 | Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. *Journal of Neurosurgery*, **1997**, 86, 747-54 | 3.2 | 470 |
| 298 | The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research. *Journal of Clinical Oncology*, **2009**, 27, 2308-18 | 2.2 | 456 |
| 297 | Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group study. *Journal of Clinical Oncology*, **2001**, 19, 3470-6 | 2.2 | 419 |
| 296 | New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. *Journal of the National Cancer Institute*, **2006**, 98, 1528-37 | 9.7 | 417 |
| 295 | Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. *Annals of Neurology*, **1997**, 41, 143-9 | 9.4 | 374 |
| 294 | Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. *Nature Genetics*, **2001**, 29, 143-52 | 36.3 | 367 |
| 293 | Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. *Journal of the National Cancer Institute*, **2009**, 101, 946-58 | 9.7 | 354 |
| 292 | Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. *Journal of Neurosurgery*, **1994**, 81, 690-8 | 3.2 | 336 |
| 291 | Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. *Journal of Clinical Oncology*, **2005**, 23, 7621-31 | 2.2 | 327 |
| 290 | Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. *Acta Neuropathologica*, **2016**, 131, 821-31 | 14.3 | 324 |
| 289 | Psychological outcomes in long-term survivors of childhood brain cancer: a report from the childhood cancer survivor study. *Journal of Clinical Oncology*, **2004**, 22, 999-1006 | 2.2 | 314 |
| 288 | Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings. *Journal of Clinical Oncology*, **2009**, 27, 2339-55 | 2.2 | 302 |

| | | | |
|---|---|---|---|
| 287 | Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study. *Cancer*, **2003**, 97, 663-73 | 6.4 | 300 |
| 286 | Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study. *Journal of Clinical Oncology*, **2006**, 24, 5277-82 | 2.2 | 295 |
| 285 | A prospective study of cognitive function in children receiving whole-brain radiotherapy and chemotherapy: 2-year results. *Journal of Neurosurgery*, **1989**, 70, 707-13 | 3.2 | 279 |
| 284 | Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. *Journal of Clinical Oncology*, **2015**, 33, 2646-54 | 2.2 | 270 |
| 283 | Long-term neurologic and neurosensory sequelae in adult survivors of a childhood brain tumor: childhood cancer survivor study. *Journal of Clinical Oncology*, **2003**, 21, 3255-61 | 2.2 | 269 |
| 282 | Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group. *Journal of Clinical Oncology*, **2012**, 30, 2641-7 | 2.2 | 265 |
| 281 | Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children's Cancer Group. *Journal of Neurosurgery*, **1998**, 88, 695-703 | 3.2 | 255 |
| 280 | Treatment of chiasmatic/hypothalamic gliomas of childhood with chemotherapy: an update. *Annals of Neurology*, **1988**, 23, 79-85 | 9.4 | 241 |
| 279 | Neurocognitive status in long-term survivors of childhood CNS malignancies: a report from the Childhood Cancer Survivor Study. *Neuropsychology*, **2009**, 23, 705-17 | 3.8 | 232 |
| 278 | Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. *Journal of Clinical Oncology*, **2000**, 18, 3004-11 | 2.2 | 227 |
| 277 | Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. *Lancet Oncology, The*, **2013**, 14, 1200-7 | 21.7 | 226 |
| 276 | Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG-945. *Journal of Neurosurgery*, **1998**, 89, 52-9 | 3.2 | 224 |
| 275 | Cerebrovascular abnormalities in a population of children with neurofibromatosis type 1. *Neurology* , **2005**, 64, 553-5 | 6.5 | 214 |
| 274 | Intracranial Germ Cell Tumors. *Oncologist*, **2000**, 5, 312-320 | 5.7 | 214 |
| 273 | Medulloblastoma in childhood: new biological advances. *Lancet Neurology, The*, **2007**, 6, 1073-85 | 24.1 | 209 |
| 272 | Optic pathway and hypothalamic/chiasmatic gliomas in children younger than age 5 years with a 6-year follow-up. *Cancer*, **1995**, 75, 1051-9 | 6.4 | 207 |
| 271 | Divergent clonal selection dominates medulloblastoma at recurrence. *Nature*, **2016**, 529, 351-7 | 50.4 | 206 |
| 270 | Long-term sequelae of cancer treatment on the central nervous system in childhood. *Medical and Pediatric Oncology*, **1987**, 15, 241-53 | | 193 |

| | | | |
|---|---|---|---|
| 269 | Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. *Neuro-Oncology*, **2012**, 14, 790-7 | 1 | 192 |
| 268 | Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. *Lancet Oncology, The*, **2016**, 17, 484-495 | 21.7 | 187 |
| 267 | Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. *Lancet Oncology, The*, **2019**, 20, 1011-1022 | 21.7 | 182 |
| 266 | A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. *Neuro-Oncology*, **2017**, 19, 1135-1144 | 1 | 180 |
| 265 | Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood. *Journal of Neuro-Oncology*, **1995**, 24, 21-8 | 4.8 | 177 |
| 264 | Magnetic Resonance Scans Should Replace Biopsies for the Diagnosis of Diffuse Brain Stem Gliomas. *Neurosurgery*, **1993**, 33, 1026-1030 | 3.2 | 176 |
| 263 | Neoadjuvant chemotherapy for newly diagnosed germ-cell tumors of the central nervous system. *Journal of Neurosurgery*, **1987**, 67, 65-70 | 3.2 | 168 |
| 262 | Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961. *Neuro-Oncology*, **2013**, 15, 97-103 | 1 | 163 |
| 261 | Long-term outcomes of adult survivors of childhood cancer. *Cancer*, **2005**, 104, 2557-64 | 6.4 | 161 |
| 260 | Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 8188-93 | 11.5 | 156 |
| 259 | Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. *Journal of Clinical Oncology*, **2010**, 28, 3069-75 | 2.2 | 155 |
| 258 | A multi-institutional retrospective study of intracranial ependymoma in children: identification of risk factors. *Journal of Pediatric Hematology/Oncology*, **1999**, 21, 203-11 | 1.2 | 154 |
| 257 | Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. *Journal of Clinical Oncology*, **2017**, 35, 2934-2941 | 2.2 | 153 |
| 256 | Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. *Nature Communications*, **2016**, 7, 11185 | 17.4 | 152 |
| 255 | Outcome of children with brain stem gliomas after treatment with 7800 cGy of hyperfractionated radiotherapy. A Childrens Cancer Group Phase I/II Trial. *Cancer*, **1994**, 74, 1827-34 | 6.4 | 151 |
| 254 | Monosomy 22 in rhabdoid or atypical tumors of the brain. *Journal of Neurosurgery*, **1990**, 73, 710-4 | 3.2 | 147 |
| 253 | Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. *Clinical Cancer Research*, **2013**, 19, 6305-12 | 12.9 | 145 |
| 252 | Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy. *Cancer*, **2000**, 88, 2189-93 | 6.4 | 143 |

| | | | |
|---|---|---|---|
| 251 | Isochromosome 17q in primitive neuroectodermal tumors of the central nervous system. *Genes Chromosomes and Cancer*, **1989**, 1, 139-47 | 5 | 139 |
| 250 | Management of and prognosis with medulloblastoma: therapy at a crossroads. *Archives of Neurology*, **2008**, 65, 1419-24 | | 137 |
| 249 | Three- and four-year cognitive outcome in children with noncortical brain tumors treated with whole-brain radiotherapy. *Annals of Neurology*, **1992**, 32, 551-4 | 9.4 | 134 |
| 248 | Incidence and severity of postoperative cerebellar mutism syndrome in children with medulloblastoma: a prospective study by the Children's Oncology Group. *Journal of Neurosurgery: Pediatrics*, **2006**, 105, 444-51 | 2.1 | 133 |
| 247 | Choroid plexus carcinoma of childhood. *Cancer*, **1992**, 69, 580-5 | 6.4 | 132 |
| 246 | Medulloblastoma: present concepts of stratification into risk groups. *Pediatric Neurosurgery*, **2003**, 39, 60-7 | 0.9 | 129 |
| 245 | Pediatric high-grade glioma: biologically and clinically in need of new thinking. *Neuro-Oncology*, **2017**, 19, 153-161 | 1 | 125 |
| 244 | Hyperfractionated radiation therapy (72 Gy) for children with brain stem gliomas. A Childrens Cancer Group Phase I/II Trial. *Cancer*, **1993**, 72, 1414-21 | 6.4 | 125 |
| 243 | Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. *Journal of Clinical Oncology*, **2018**, 36, 1963-1972 | 2.2 | 125 |
| 242 | Final height and body mass index among adult survivors of childhood brain cancer: childhood cancer survivor study. *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 4731-9 | 5.6 | 122 |
| 241 | Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a Children's Oncology Group Phase I/II study. *Journal of Clinical Oncology*, **2012**, 30, 2648-53 | 2.2 | 121 |
| 240 | Cognitive deficits in long-term survivors of childhood brain tumors. *Childs Nervous System*, **1991**, 7, 2-12 | 1.7 | 121 |
| 239 | Updated results of a pilot study of low dose craniospinal irradiation plus chemotherapy for children under five with cerebellar primitive neuroectodermal tumors (medulloblastoma). *International Journal of Radiation Oncology Biology Physics*, **1996**, 34, 899-904 | 4 | 120 |
| 238 | Leptomeningeal dissemination of primary central nervous system tumors of childhood. *Annals of Neurology*, **1985**, 18, 217-21 | 9.4 | 115 |
| 237 | Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. *Journal of Clinical Oncology*, **2016**, 34, 2468-77 | 2.2 | 113 |
| 236 | Cerebral gangliogliomas during childhood. *Neurosurgery*, **1983**, 13, 124-8 | 3.2 | 113 |
| 235 | Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. *Pediatric Blood and Cancer*, **2009**, 52, 791-5 | 3 | 108 |
| 234 | Magnetic resonance imaging in the evaluation of treatment-related central nervous system damage. *Cancer*, **1986**, 58, 635-40 | 6.4 | 107 |

| | | | |
|---|---|---|---|
| 233 | Results of a prospective randomized trial comparing standard dose neuraxis irradiation (3,600 cGy/20) with reduced neuraxis irradiation (2,340 cGy/13) in patients with low-stage medulloblastoma. A Combined Children's Cancer Group-Pediatric Oncology Group Study. *Pediatric Neurosurgery*, **1996**, 24, 167-175; discussion 176-7 | 0.9 | 106 |
| 232 | Radiation, atherosclerotic risk factors, and stroke risk in survivors of pediatric cancer: a report from the Childhood Cancer Survivor Study. *International Journal of Radiation Oncology Biology Physics*, **2013**, 86, 649-55 | 4 | 105 |
| 231 | Correlation of neurosurgical subspecialization with outcomes in children with malignant brain tumors. *Neurosurgery*, **2000**, 47, 879-85; discussion 885-7 | 3.2 | 104 |
| 230 | Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study. *Neuro-Oncology*, **2014**, 16, 310-7 | 1 | 103 |
| 229 | Region-specific radiotherapy and neuropsychological outcomes in adult survivors of childhood CNS malignancies. *Neuro-Oncology*, **2010**, 12, 1173-86 | 1 | 97 |
| 228 | Growth hormone replacement therapy in children with medulloblastoma: use and effect on tumor control. *Journal of Clinical Oncology*, **2001**, 19, 480-7 | 2.2 | 96 |
| 227 | Clinical, cytogenetic, and pedigree findings in 18 cases of Aicardi syndrome. *American Journal of Medical Genetics Part A*, **1989**, 32, 461-7 | | 95 |
| 226 | The effects of adjuvant chemotherapy on growth in children with medulloblastoma. *Cancer*, **1992**, 70, 2013-7 | 6.4 | 94 |
| 225 | The cerebellar mutism syndrome and its relation to cerebellar cognitive function and the cerebellar cognitive affective disorder. *Developmental Disabilities Research Reviews*, **2008**, 14, 221-8 | | 93 |
| 224 | Pilot Study of Intensive Chemotherapy With Peripheral Hematopoietic Cell Support for Children Less Than 3 Years of Age With Malignant Brain Tumors, the CCG-99703 Phase I/II Study. A Report From the Children's Oncology Group. *Pediatric Neurology*, **2015**, 53, 31-46 | 2.9 | 92 |
| 223 | Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study. *Neuro-Oncology*, **2015**, 17, 596-603 | 1 | 91 |
| 222 | Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. *Pediatric Blood and Cancer*, **2013**, 60, 776-82 | 3 | 91 |
| 221 | Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective. *Neuro-Oncology*, **2008**, 10, 1040-60 | 1 | 91 |
| 220 | Postoperative cerebellar mutism syndrome following treatment of medulloblastoma: neuroradiographic features and origin. *Journal of Neurosurgery: Pediatrics*, **2010**, 5, 329-34 | 2.1 | 90 |
| 219 | Quality of long-term survival in young children with medulloblastoma. *Journal of Neurosurgery*, **1994**, 80, 1004-10 | 3.2 | 90 |
| 218 | Primitive neuroectodermal tumors of the central nervous system. *Brain Pathology*, **1997**, 7, 765-84 | 6 | 83 |
| 217 | Brain tumors in children. *Archives of Neurology*, **1999**, 56, 421-5 | | 82 |
| 216 | Spatial heterogeneity in medulloblastoma. *Nature Genetics*, **2017**, 49, 780-788 | 36.3 | 80 |

| | | | |
|---|---|---|---|
| 215 | DIPG-70. CLINICAL, RADIOLOGICAL, PATHOLOGICAL AND MOLECULAR CHARACTERISTICS OF CHILDREN . *Neuro-Oncology*, **2018**, 20, i63-i63 | 1 | 78 |
| 214 | MBCL-15. IMPACT OF MOLECULAR SUBGROUPS ON OUTCOMES FOLLOWING RADIATION TREATMENT RANDOMIZATIONS FOR AVERAGE RISK MEDULLOBLASTOMA: A PLANNED ANALYSIS OF CHILDREN'S ONCOLOGY GROUP (COG) ACNS0331. *Neuro-Oncology*, **2020**, 22, iii391-iii391 | 1 | 78 |
| 213 | LGG-26. DIFFUSE LEPTOMENINGEAL GLIONEURONAL TUMOR (DLGNT) IN CHILDREN: DIFFERENT CLINICAL PRESENTATIONS AND OUTCOMES. *Neuro-Oncology*, **2020**, 22, iii371-iii371 | 1 | 78 |
| 212 | GCT-23. MULTI-INSTITUTIONAL ANALYSIS OF TREATMENT MODALITIES IN BASAL GANGLIA AND THALAMIC GERMINOMA. *Neuro-Oncology*, **2020**, 22, iii332-iii332 | 1 | 78 |
| 211 | EMBR-02. OLIG2 REPRESENTS A PROGNOSTIC MARKER AND THERAPEUTIC TARGET IN MYC-AMPLIFIED MEDULLOBLASTOMA RELAPSE AND METASTASIS. *Neuro-Oncology*, **2021**, 23, i5-i6 | 1 | 78 |
| 210 | DIPG-53. COMPREHENSIVE CLINICAL AND MOLECULAR ANALYSIS OF PEDIATRIC THALAMIC GLIOMA. *Neuro-Oncology*, **2018**, 20, i59-i60 | 1 | 78 |
| 209 | CRAN-16. IMPORTANCE OF SURGICAL INTERVENTION IN RECOVERY OF VISUAL FUNCTION IN A TEENAGER WITH AN ACIDOPHILIC STEM CELL ADENOMA. *Neuro-Oncology*, **2018**, 20, i39-i40 | 1 | 78 |
| 208 | PDTM-13. OVEREXPRESSION OF MYC ALONE IS SUFFICIENT TO INITIATE GROUP 3 MEDULLOBLASTOMA. *Neuro-Oncology*, **2018**, 20, vi206-vi206 | 1 | 78 |
| 207 | PDTM-15. IDENTIFICATION AND CHARACTERIZATION OF WILMS' TUMOR PROTEIN IN PEDIATRIC MIDLINE GLIOMAS. *Neuro-Oncology*, **2018**, 20, vi206-vi207 | 1 | 78 |
| 206 | EMBR-01. MOLECULAR AND CLINICAL HETEROGENEITY IN HISTOLOGICALLY-DIAGNOSED CNS-PNET PATIENTS PROSPECTIVELY TREATED AS A SINGLE ENTITY: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP ACNS0332 TRIAL. *Neuro-Oncology*, **2018**, 20, i68-i69 | 1 | 78 |
| 205 | Chemotherapy for medulloblastoma/primitive neuroectodermal tumors of the posterior fossa. *Annals of Neurology*, **1990**, 28, 823-8 | 9.4 | 77 |
| 204 | Pediatric low-grade gliomas: next biologically driven steps. *Neuro-Oncology*, **2018**, 20, 160-173 | 1 | 76 |
| 203 | Pediatric Brain Tumors. *Neurologic Clinics*, **2018**, 36, 533-556 | 4.5 | 75 |
| 202 | Current treatment of medulloblastoma: recent advances and future challenges. *Seminars in Oncology*, **2004**, 31, 666-75 | 5.5 | 74 |
| 201 | Marked recovery of vision in children with optic pathway gliomas treated with bevacizumab. *JAMA Ophthalmology*, **2014**, 132, 111-4 | 3.9 | 73 |
| 200 | Efficacy of adjuvant chemotherapy for patients with poor-risk medulloblastoma: a preliminary report. *Annals of Neurology*, **1988**, 24, 503-8 | 9.4 | 72 |
| 199 | Hyperfractionated radiotherapy for children with brainstem gliomas: a pilot study using 7,200 cGy. *Annals of Neurology*, **1990**, 27, 167-73 | 9.4 | 71 |
| 198 | Clinical, Pathological, and Molecular Characterization of Infant Medulloblastomas Treated with Sequential High-Dose Chemotherapy. *Pediatric Blood and Cancer*, **2016**, 63, 1527-34 | 3 | 71 |

| | | | |
|---|---|---|---|
| 197 | Advances in the diagnosis, molecular genetics, and treatment of pediatric embryonal CNS tumors. *Oncologist*, **2003**, 8, 174-86 | 5.7 | 69 |
| 196 | Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration. *Journal of Neurosurgery*, **2000**, 92, 249-54 | 3.2 | 69 |
| 195 | Intellectual and academic outcome following two chemotherapy regimens and radiotherapy for average-risk medulloblastoma: COG A9961. *Pediatric Blood and Cancer*, **2013**, 60, 1350-7 | 3 | 67 |
| 194 | Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: A report from the Children's Oncology Group. *Cancer*, **2016**, 122, 1928-36 | 6.4 | 67 |
| 193 | Pineocytomas of childhood. A reappraisal of natural history and response to therapy. *Cancer*, **1987**, 59, 1353-7 | 6.4 | 66 |
| 192 | Ocular late effects in childhood and adolescent cancer survivors: a report from the childhood cancer survivor study. *Pediatric Blood and Cancer*, **2010**, 54, 103-9 | 3 | 65 |
| 191 | Intracranial neoplasms in children with neurofibromatosis 1. *Journal of Child Neurology*, **2002**, 17, 630-7; discussion 646-51 | 2.5 | 65 |
| 190 | Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. *Cancer Discovery*, **2020**, 10, 942-963 | 24.4 | 65 |
| 189 | Children's Oncology Group's 2013 blueprint for research: central nervous system tumors. *Pediatric Blood and Cancer*, **2013**, 60, 1022-6 | 3 | 64 |
| 188 | Treatment of children with newly diagnosed brain stem gliomas with intravenous recombinant beta-interferon and hyperfractionated radiation therapy: a childrens cancer group phase I/II study. *Cancer*, **1996**, 77, 2150-6 | 6.4 | 62 |
| 187 | Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. *Clinical Cancer Research*, **2009**, 15, 5032-5039 | 12.9 | 61 |
| 186 | Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. *Neuro-Oncology*, **2011**, 13, 298-306 | 1 | 61 |
| 185 | Quality of life of adult survivors of germinomas treated with craniospinal irradiation. *Neurosurgery*, **1999**, 45, 1292-7; discussion 1297-8 | 3.2 | 59 |
| 184 | Suprasellar germinomas in childhood. A reappraisal. *Cancer*, **1989**, 63, 340-4 | 6.4 | 58 |
| 183 | Results of treatment of children with recurrent medulloblastoma/primitive neuroectodermal tumors with lomustine, cisplatin, and vincristine. *Cancer*, **1990**, 65, 412-7 | 6.4 | 58 |
| 182 | Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. *Journal of Clinical Oncology*, **2007**, 25, 3137-43 | 2.2 | 56 |
| 181 | Childhood brain tumors: accomplishments and ongoing challenges. *Journal of Child Neurology*, **2008**, 23, 1122-7 | 2.5 | 55 |
| 180 | Primitive neuroectodermal tumors of the central nervous system express neuroendocrine markers and may express all classes of intermediate filaments. *Human Pathology*, **1990**, 21, 245-52 | 3.7 | 55 |

| | | | |
|---|---|---|---|
| 179 | Treatment of diencephalic syndrome with chemotherapy: growth, tumor response, and long term control. *Cancer*, **1998**, 83, 166-72 | 6.4 | 54 |
| 178 | Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1. *Neurology*, **2016**, 87, 2575-2584 | 6.5 | 53 |
| 177 | Challenges with defining response to antitumor agents in pediatric neuro-oncology: a report from the response assessment in pediatric neuro-oncology (RAPNO) working group. *Pediatric Blood and Cancer*, **2013**, 60, 1397-401 | 3 | 53 |
| 176 | Chemotherapy with vincristine (VCR) and etoposide (VP-16) in children with low-grade astrocytoma. *Journal of Neuro-Oncology*, **1992**, 14, 151-8 | 4.8 | 52 |
| 175 | Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma: final analysis of Children's Cancer Group Study 9933. *Cancer*, **2005**, 104, 2862-71 | 6.4 | 51 |
| 174 | Chemotherapy for low-grade gliomas. *Childs Nervous System*, **1999**, 15, 506-13 | 1.7 | 51 |
| 173 | A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study. *Journal of Neuro-Oncology*, **2016**, 129, 443-451 | 4.8 | 50 |
| 172 | Neurocognitive dysfunction in children with neurofibromatosis type 1. *Current Neurology and Neuroscience Reports*, **2003**, 3, 129-36 | 6.6 | 50 |
| 171 | Endocrine outcome in children with medulloblastoma treated with 18 Gy of craniospinal radiation therapy. *Neuro-Oncology*, **2004**, 6, 113-8 | 1 | 49 |
| 170 | A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG). *Pediatric Blood and Cancer*, **2013**, 60, 71-6 | 3 | 48 |
| 169 | Handheld optical coherence tomography during sedation in young children with optic pathway gliomas. *JAMA Ophthalmology*, **2014**, 132, 265-71 | 3.9 | 48 |
| 168 | Results of the treatment of children with recurrent gliomas with lomustine and vincristine. *Cancer*, **1988**, 61, 896-902 | 6.4 | 48 |
| 167 | Management of children with primitive neuroectodermal tumors of the posterior fossa/medulloblastoma. *Pediatric Neurosurgery*, **1985**, 12, 272-82 | 0.9 | 48 |
| 166 | Outcome and prognostic factors for children with supratentorial primitive neuroectodermal tumors treated with carboplatin during radiotherapy: a report from the Children's Oncology Group. *Pediatric Blood and Cancer*, **2015**, 62, 776-83 | 3 | 47 |
| 165 | A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study. *Journal of Neuro-Oncology*, **2013**, 114, 173-9 | 4.8 | 47 |
| 164 | Pediatric low-grade gliomas: implications of the biologic era. *Neuro-Oncology*, **2017**, 19, 750-761 | 1 | 47 |
| 163 | A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. *European Journal of Cancer*, **2010**, 46, 3287-93 | 7.5 | 46 |
| 162 | High dose systemic methotrexate-associated acute neurologic dysfunction. *Medical and Pediatric Oncology*, **1983**, 11, 159-61 | | 46 |

| | | | |
|---|---|---|---|
| 161 | Vascular malformation with radiation vasculopathy after treatment of chiasmatic/hypothalamic glioma. *Cancer*, **1992**, 70, 887-93 | 6.4 | 45 |
| 160 | Incidence, Presentation, and Outcome of Spinal Cord Disease in Children With Systemic Cancer. *Pediatrics*, **1986**, 78, 438-443 | 7.4 | 45 |
| 159 | Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. *Lancet Oncology, The*, **2020**, 21, e305-e316 | 21.7 | 43 |
| 158 | Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee. *Neuro-Oncology*, **2018**, 20, 13-23 | 7 | 43 |
| 157 | Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study. *Neuro-Oncology*, **2017**, 19, 1279-1280 | 1 | 43 |
| 156 | Early cystic/necrotic changes after hyperfractionated radiation therapy in children with brain stem gliomas. Data from the Childrens Cancer Group. *Cancer*, **1993**, 71, 2666-74 | 6.4 | 43 |
| 155 | Oligodendroglioma of the posterior fossa in childhood. *Cancer*, **1985**, 56, 195-9 | 6.4 | 42 |
| 154 | A Phase I study of concurrent RMP-7 and carboplatin with radiation therapy for children with newly diagnosed brainstem gliomas. *Cancer*, **2005**, 104, 1968-74 | 6.4 | 41 |
| 153 | Results of a pilot study of low-dose craniospinal radiation therapy plus chemotherapy for children younger than 5 years with primitive neuroectodermal tumors. *Cancer*, **1993**, 71, 2647-52 | 6.4 | 41 |
| 152 | Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma. *Journal of Clinical Oncology*, **2019**, 37, 3446-3454 | 2.2 | 40 |
| 151 | Outcome for children . *Pediatric Blood and Cancer*, **2007**, 48, 278-84 | 3 | 40 |
| 150 | An integrated approach to the treatment of chiasmatic-hypothalamic gliomas. *Journal of Neuro-Oncology*, **1996**, 28, 167-83 | 4.8 | 40 |
| 149 | Intracranial embryonal cell carcinoma. *Cancer*, **1984**, 54, 520-4 | 6.4 | 40 |
| 148 | Long-term neurologic health and psychosocial function of adult survivors of childhood medulloblastoma/PNET: a report from the Childhood Cancer Survivor Study. *Neuro-Oncology*, **2017**, 19, 689-698 | 1 | 39 |
| 147 | Late Morbidity and Mortality Among Medulloblastoma Survivors Diagnosed Across Three Decades: A Report From the Childhood Cancer Survivor Study. *Journal of Clinical Oncology*, **2019**, 37, 731-740 | 2.2 | 38 |
| 146 | Auditory complications in childhood cancer survivors: a report from the childhood cancer survivor study. *Pediatric Blood and Cancer*, **2011**, 57, 126-34 | 3 | 38 |
| 145 | A multi-institutional study of brainstem gliomas in children with neurofibromatosis type 1. *Neurology*, **2017**, 88, 1584-1589 | 6.5 | 37 |
| 144 | A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation. *Acta Neuropathologica*, **2015**, 130, 575-85 | 14.3 | 37 |

| | | | |
|---|---|---|---|
| 143 | Microphthalmia and chorioretinal lesions in a girl with an Xp22.2-pter deletion and partial 3p trisomy: clinical observations relevant to Aicardi syndrome gene localization. *American Journal of Medical Genetics Part A*, **1990**, 37, 182-6 | | 37 |
| 142 | Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001). *Journal of Clinical Oncology*, **2005**, 23, 525-31 | 2.2 | 36 |
| 141 | Treatment developments and the unfolding of the quality of life discussion in childhood medulloblastoma: a review. *Childs Nervous System*, **2014**, 30, 979-90 | 1.7 | 35 |
| 140 | Central nervous system tumors. *Pediatric Clinics of North America*, **2008**, 55, 121-45, xi | 3.6 | 35 |
| 139 | Late recurrence of primitive neuroectodermal tumor/medulloblastoma. *Cancer*, **1988**, 62, 826-30 | 6.4 | 35 |
| 138 | Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Children's Oncology Group Randomized ACNS0332 Trial. *Journal of Clinical Oncology*, **2018**, JCO2017764720 | 2.2 | 34 |
| 137 | Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma. *Neuro-Oncology*, **2014**, 16, 1554-9 | 1 | 33 |
| 136 | Pilocytic astrocytomas. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2016**, 134, 329-44 | 3 | 33 |
| 135 | Longitudinal assessment of late-onset neurologic conditions in survivors of childhood central nervous system tumors: a Childhood Cancer Survivor Study report. *Neuro-Oncology*, **2018**, 20, 132-142 | 1 | 32 |
| 134 | Treatment Options for Medulloblastoma and CNS Primitive Neuroectodermal Tumor (PNET). *Current Treatment Options in Neurology*, **2013**, 15, 593-606 | 4.4 | 32 |
| 133 | Primary spinal cord tumors of childhood: effects of clinical presentation, radiographic features, and pathology on survival. *Journal of Neuro-Oncology*, **2009**, 95, 259-269 | 4.8 | 32 |
| 132 | Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors. *Pediatric Blood and Cancer*, **2009**, 52, 169-76 | 3 | 32 |
| 131 | Phase I trial of lobradimil (RMP-7) and carboplatin in children with brain tumors. *Cancer Chemotherapy and Pharmacology*, **2001**, 48, 275-82 | 3.5 | 32 |
| 130 | Medulloblastoma and primitive neuroectodermal tumors. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2012**, 105, 529-48 | 3 | 31 |
| 129 | Neurologic complications in children with soft tissue and osseous sarcoma. *Cancer*, **1989**, 64, 2600-3 | 6.4 | 31 |
| 128 | SHH inhibitors for the treatment of medulloblastoma. *Expert Review of Neurotherapeutics*, **2015**, 15, 763-79 | 4.9 | 30 |
| 127 | A pilot study using carboplatin, vincristine, and temozolomide in children with progressive/symptomatic low-grade glioma: a Children's Oncology Group study *Neuro-Oncology*, **2015**, 17, 1132-8 | 1 | 28 |
| 126 | Chemotherapy: low-grade gliomas of the hypothalamus and thalamus. *Pediatric Neurosurgery*, **2000**, 32, 259-63 | 0.9 | 28 |

| | | | |
|---|---|---|---|
| 125 | Advances in the management of low-grade gliomas. *Current Oncology Reports*, **2014**, 16, 398 | 6.3 | 27 |
| 124 | Phase 1 study of concurrent RMP-7 and carboplatin with radiotherapy for children with newly diagnosed brainstem gliomas. *Cancer*, **2005**, 104, 1281-7 | 6.4 | 27 |
| 123 | Visual outcomes in children with neurofibromatosis type 1 and orbitotemporal plexiform neurofibromas. *American Journal of Ophthalmology*, **2013**, 155, 1089-1094.e1 | 4.9 | 26 |
| 122 | Cumulative cisplatin dose is not associated with event-free or overall survival in children with newly diagnosed average-risk medulloblastoma treated with cisplatin based adjuvant chemotherapy: report from the Children's Oncology Group. *Pediatric Blood and Cancer*, **2014**, 61, 102-6 | 3 | 26 |
| 121 | Therapy for plexiform neurofibromas in children with neurofibromatosis 1: an overview. *Journal of Child Neurology*, **2002**, 17, 638-41; discussion 646-51 | 2.5 | 26 |
| 120 | An animal model to detect the neuropsychological toxicity of anticancer agents. *Medical and Pediatric Oncology*, **1989**, 17, 216-21 | | 26 |
| 119 | Pediatric brain tumors and epilepsy. *Seminars in Pediatric Neurology*, **2012**, 19, 3-8 | 2.9 | 25 |
| 118 | Impact of tumor location and pathological discordance on survival of children with midline high-grade gliomas treated on Children's Cancer Group high-grade glioma study CCG-945. *Journal of Neuro-Oncology*, **2015**, 121, 573-81 | 4.8 | 24 |
| 117 | Progress and challenges in childhood brain tumors. *Journal of Neuro-Oncology*, **2005**, 75, 239-42 | 4.8 | 24 |
| 116 | Acute Mental Status Changes in Children With Systemic Cancer. *Pediatrics*, **1990**, 85, 353-360 | 7.4 | 24 |
| 115 | Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition. *JCO Precision Oncology*, **2020**, 4, | 3.6 | 23 |
| 114 | Antioxidant enzyme polymorphisms and neuropsychological outcomes in medulloblastoma survivors: a report from the Childhood Cancer Survivor Study. *Neuro-Oncology*, **2012**, 14, 1018-25 | 1 | 23 |
| 113 | Primary Central Nervous System Tumors in Children. *Current Treatment Options in Neurology*, **1999**, 1, 395-408 | 4.4 | 23 |
| 112 | Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. *Neuro-Oncology*, **2020**, 22, 773-784 | 1 | 21 |
| 111 | Long-term neuropsychological follow-up of young children with medulloblastoma treated with sequential high-dose chemotherapy and irradiation sparing approach. *Journal of Neuro-Oncology*, **2017**, 133, 119-128 | 4.8 | 20 |
| 110 | A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. *Neuro-Oncology*, **2020**, 22, 1527-1535 | 1 | 20 |
| 109 | Biologically targeted therapeutics in pediatric brain tumors. *Pediatric Neurology*, **2012**, 46, 203-11 | 2.9 | 19 |
| 108 | Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. *Nature Medicine*, **2021**, 27, 165-173 | 50.5 | 19 |

| | | | |
|---|---|---|---|
| 107 | Medulloblastoma: toward biologically based management. *Seminars in Pediatric Neurology*, **2015**, 22, 6-13 | 2.9 | 17 |
| 106 | Neurofibromatosis type 1 and optic pathway glioma: Molecular interplay and therapeutic insights. *Pediatric Blood and Cancer*, **2018**, 65, e26838 | 3 | 17 |
| 105 | Proteomic profiling of high risk medulloblastoma reveals functional biology. *Oncotarget*, **2015**, 6, 14584-95 | 3.3 | 17 |
| 104 | Medulloblastoma. *Current Opinion in Neurology*, **1999**, 12, 681-5 | 7.1 | 17 |
| 103 | Autism-associated Nf1 deficiency disrupts corticocortical and corticostriatal functional connectivity in human and mouse. *Neurobiology of Disease*, **2019**, 130, 104479 | 7.5 | 16 |
| 102 | Spinal cord compression in widely metastatic Wilms' tumor. Paraplegia in two children with anaplastic Wilms' tumor. *Cancer*, **1992**, 69, 2726-30 | 6.4 | 16 |
| 101 | NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. *Journal of Clinical Oncology*, **2021**, 39, 797-806 | 2.2 | 16 |
| 100 | MB-109PRELIMINARY RESULTS OF COG ACNS0331: A PHASE III TRIAL OF INVOLVED FIELD RADIOTHERAPY (IFRT) AND LOW DOSE CRANIOSPINAL IRRADIATION (LD-CSI) WITH CHEMOTHERAPY IN AVERAGE RISK MEDULLOBLASTOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP. *Neuro-Oncology*, **2016**, 18, iii122-iii122 | 1 | 16 |
| 99 | Quantitative MRI criteria for optic pathway enlargement in neurofibromatosis type 1. *Neurology*, **2016**, 86, 2264-70 | 6.5 | 16 |
| 98 | Central nervous system and Langerhans' cell histiocytosis. *Medical and Pediatric Oncology*, **1990**, 18, 325-8 | | 15 |
| 97 | Liquid biopsy for pediatric central nervous system tumors. *Npj Precision Oncology*, **2018**, 2, 29 | 9.8 | 15 |
| 96 | Radiation-induced neurocognitive decline: the risks and benefits of reducing the amount of whole-brain irradiation. *Current Neurology and Neuroscience Reports*, **2002**, 2, 131-3 | 6.6 | 14 |
| 95 | Etoposide with or without mannitol for the treatment of recurrent or primarily unresponsive brain tumors: a Children's Cancer Group Study, CCG-9881. *Journal of Neuro-Oncology*, **1999**, 45, 47-54 | 4.8 | 14 |
| 94 | Chemotherapy for Childhood Medulloblastoma and Primitive Neuroectodermal Tumors. *Oncologist*, **1996**, 1, 381-393 | 5.7 | 14 |
| 93 | Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study. *Journal of Neuro-Oncology*, **2015**, 121, 217-24 | 4.8 | 13 |
| 92 | Case-based review: pediatric medulloblastoma. *Neuro-Oncology Practice*, **2017**, 4, 138-150 | 2.2 | 13 |
| 91 | Magnetic resonance imaging in the evaluation of intracranial tumors of childhood. *Cancer*, **1985**, 56, 1767-72 | 6.4 | 13 |
| 90 | MR imaging features of diffuse intrinsic pontine glioma and relationship to overall survival: report from the International DIPG Registry. *Neuro-Oncology*, **2020**, 22, 1647-1657 | 1 | 12 |

| | | | |
|---|---|---|---|
| 89 | Risk stratification of medulloblastoma: a paradigm for future childhood brain tumor management strategies. *Current Neurology and Neuroscience Reports*, **2011**, 11, 124-6 | 6.6 | 12 |
| 88 | Fatal brain stem necrosis after standard posterior fossa radiation and aggressive chemotherapy for metastatic medulloblastoma. *Cancer*, **1993**, 71, 4111-7 | 6.4 | 12 |
| 87 | Children's Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma. *Journal of Clinical Oncology*, **2021**, 39, 2685-2697 | 2.2 | 12 |
| 86 | Targeted therapy for infants with diencephalic syndrome: A case report and review of management strategies. *Pediatric Blood and Cancer*, **2018**, 65, e26917 | 3 | 11 |
| 85 | NFM-06. NF106: PHASE 2 TRIAL OF THE MEK INHIBITOR PD-0325901 IN ADOLESCENTS AND ADULTS WITH NF1-RELATED PLEXIFORM NEUROFIBROMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY. *Neuro-Oncology*, **2018**, 20, i143-i143 | 1 | 11 |
| 84 | Neurotoxicity of biologically targeted agents in pediatric cancer trials. *Pediatric Neurology*, **2012**, 46, 212-21 | 2.9 | 10 |
| 83 | Central nervous system tumors. *Hematology/Oncology Clinics of North America*, **2010**, 24, 87-108 | 3.1 | 10 |
| 82 | Alternative therapies for children with brain stem gliomas: immunotherapy and gene therapy. *Pediatric Neurosurgery*, **1996**, 24, 217-22 | 0.9 | 10 |
| 81 | Computerized cognitive training for children with neurofibromatosis type 1: A pilot resting-state fMRI study. *Psychiatry Research - Neuroimaging*, **2017**, 266, 53-58 | 2.9 | 9 |
| 80 | Drives Group 3 Medulloblastoma through Transformation of Sox2 Astrocyte Progenitor Cells. *Cancer Research*, **2019**, 79, 1967-1980 | 10.1 | 9 |
| 79 | Progress in the treatment of childhood brain tumors: no room for complacency. *Pediatric Hematology and Oncology*, **2007**, 24, 79-84 | 1.7 | 9 |
| 78 | Current approaches to CNS tumors in infants and very young children. *Expert Review of Neurotherapeutics*, **2004**, 4, 681-90 | 4.3 | 9 |
| 77 | A phase 1 study of AZD6244 in children with recurrent or refractory low-grade gliomas: A Pediatric Brain Tumor Consortium report.. *Journal of Clinical Oncology*, **2014**, 32, 10065-10065 | 2.2 | 9 |
| 76 | Impact of molecular biology studies on the understanding of brain tumors in childhood. *Current Oncology Reports*, **2012**, 14, 206-12 | 6.3 | 8 |
| 75 | Radiation therapy quality in CCG/POG intergroup 9961: implications for craniospinal irradiation and the posterior fossa boost in future medulloblastoma trials. *Frontiers in Oncology*, **2012**, 2, 185 | 5.3 | 8 |
| 74 | Cerebellar sclerosis in pediatric cancer patients. *Journal of Neuro-Oncology*, **1987**, 4, 353-60 | 4.8 | 8 |
| 73 | High Incidence of Veno-Occlusive Disease With Myeloablative Chemotherapy Following Craniospinal Irradiation in Children With Newly Diagnosed High-Risk CNS Embryonal Tumors: A Report From the Children's Oncology Group (CCG-99702). *Pediatric Blood and Cancer*, **2016**, 63, 1563-70 | 3 | 8 |
| 72 | Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma: A Randomized Clinical Trial From the Children's Oncology Group. *JAMA Oncology*, **2021**, 7, 1313-1321 | 13.4 | 8 |

| | | | |
|---|---|---|---|
| 71 | Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma. *Current Neurology and Neuroscience Reports*, **2007**, 7, 130, 132 | 6.6 | 8 |
| 70 | Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy. *Current Neurology and Neuroscience Reports*, **2007**, 7, 129-132 | 6.6 | 7 |
| 69 | A prospective phase II study to determine the efficacy of GDC 0449 (vismodegib) in adults with recurrent medulloblastoma (MB): A Pediatric Brain Tumor Consortium study (PBTC 25B).. *Journal of Clinical Oncology*, **2013**, 31, 2035-2035 | 2.2 | 7 |
| 68 | Histological and molecular analysis of a progressive diffuse intrinsic pontine glioma and synchronous metastatic lesions: a case report. *Oncotarget*, **2016**, 7, 42837-42842 | 3.3 | 7 |
| 67 | Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. *Journal of Clinical Oncology*, **2021**, 39, 807-821 | 2.2 | 7 |
| 66 | Optic pathway-hypothalamic glioma hemorrhage: a series of 9 patients and review of the literature. *Journal of Neurosurgery*, **2018**, 129, 1407-1415 | 3.2 | 6 |
| 65 | Radiation therapy for pediatric low-grade gliomas: survival and sequelae. *Current Neurology and Neuroscience Reports*, **2010**, 10, 10-3 | 6.6 | 6 |
| 64 | Alternative treatments for childhood brain tumors. *Childks Nervous System*, **1999**, 15, 789-94 | 1.7 | 6 |
| 63 | MRI Features of Histologically Diagnosed Supratentorial Primitive Neuroectodermal Tumors and Pineoblastomas in Correlation with Molecular Diagnoses and Outcomes: A Report from the Children's Oncology Group ACNS0332 Trial. *American Journal of Neuroradiology*, **2019**, 40, 1796-1803 | 4.4 | 6 |
| 62 | Treatment during a developmental window prevents NF1-associated optic pathway gliomas by targeting Erk-dependent migrating glial progenitors. *Developmental Cell*, **2021**, 56, 2871-2885.e6 | 10.2 | 6 |
| 61 | Harmonization of postmortem donations for pediatric brain tumors and molecular characterization of diffuse midline gliomas. *Scientific Reports*, **2020**, 10, 10954 | 4.9 | 5 |
| 60 | Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials. *JAMA Neurology*, **2020**, 77, 755-763 | 17.2 | 5 |
| 59 | A review of secondary central nervous system tumors after treatment of a primary pediatric malignancy. *Seminars in Pediatric Neurology*, **2012**, 19, 43-8 | 2.9 | 5 |
| 58 | New insights into childhood ependymomas. *Current Neurology and Neuroscience Reports*, **2005**, 5, 107-9 | 6.6 | 5 |
| 57 | Update on Pediatric Brain Tumors: the Molecular Era and Neuro-immunologic Beginnings. *Current Neurology and Neuroscience Reports*, **2020**, 20, 30 | 6.6 | 4 |
| 56 | Molecular-Targeted Therapy for Childhood Brain Tumors: A Moving Target. *Journal of Child Neurology*, **2020**, 35, 791-798 | 2.5 | 4 |
| 55 | Medulloblastoma/Primitive neuroectodermal tumor and germ cell tumors: the uncommon but potentially curable primary brain tumors. *Hematology/Oncology Clinics of North America*, **2012**, 26, 881-93 | 3.1 | 4 |
| 54 | Unsupervised MRI Homogenization: Application to Pediatric Anterior Visual Pathway Segmentation. *Lecture Notes in Computer Science*, **2020**, 12436, 180-188 | 0.9 | 4 |

| | | | |
|---|---|---|---|
| 53 | Response to Harreld re: "Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology Committee". *Neuro-Oncology*, **2018**, 20, 144-145 | 1 | 3 |
| 52 | Reduction of health status 7 years after addition of chemotherapy to cranio-spinal irradiation for medulloblastoma: a follow-up study on PNET-3 trial survivors. *Current Neurology and Neuroscience Reports*, **2008**, 8, 111-3 | 6.6 | 3 |
| 51 | New Treatments in Pediatric Brain Tumors. *Current Treatment Options in Neurology*, **2004**, 6, 377-389 | 4.4 | 3 |
| 50 | The impact of molecular analysis on the survival of children with embryonal tumors. *Translational Pediatrics*, **2016**, 5, 5-8 | 4.2 | 3 |
| 49 | Pediatric diffuse leptomeningeal glioneuronal tumor: Two clinical cases of successful targeted therapy. *Pediatric Blood and Cancer*, **2020**, 67, e28478 | 3 | 3 |
| 48 | Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1-associated optic pathway gliomas in children. *Pediatric Blood and Cancer*, **2021**, 68, e28833 | 3 | 3 |
| 47 | NFM-01. NF105: A PHASE II PROSPECTIVE STUDY OF CABOZANTINIB (XL184) FOR PLEXIFORM NEUROFIBROMAS IN SUBJECTS WITH NEUROFIBROMATOSIS TYPE 1: A NEUROFIBROMATOSIS CLINICAL TRIAL CONSORTIUM (NFCTC) STUDY. *Neuro-Oncology*, **2018**, 20, i142-i142 | 1 | 3 |
| 46 | Craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. *Current Neurology and Neuroscience Reports*, **2007**, 7, 130-2 | 6.6 | 3 |
| 45 | LGG-02. A PHASE II PROSPECTIVE TRIAL OF SELUMETINIB IN CHILDREN WITH RECURRENT/PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMA (PLGG) WITH A FOCUS UPON OPTIC PATHWAY/HYPOTHALAMIC TUMORS AND VISUAL ACUITY OUTCOMES: A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY, PBTC-029B. *Neuro-Oncology*, **2019**, 21, ii98-ii99 | 1 | 2 |
| 44 | Visual spatial learning outcomes for clinical trials in neurofibromatosis type 1. *Annals of Clinical and Translational Neurology*, **2020**, 7, 245-249 | 5.3 | 2 |
| 43 | Immunotherapy Approaches for Pediatric CNS Tumors and Associated Neurotoxicity. *Pediatric Neurology*, **2020**, 107, 7-15 | 2.9 | 2 |
| 42 | Is postoperative chemotherapy alone sufficient to treat young children with medulloblastoma?. *Nature Clinical Practice Oncology*, **2005**, 2, 386-7 | | 2 |
| 41 | Translational/Clinical Studies in Children and Adults with Neurofibromatosis Type 1 **2012**, 625-657 | | 2 |
| 40 | Subgroup and subtype-specific outcomes in adult medulloblastoma. *Acta Neuropathologica*, **2021**, 142, 859-871 | 14.3 | 2 |
| 39 | Pediatric Neuro-oncology: An Overview **2017**, 957-962 | | 1 |
| 38 | Temozolomide for pediatric high-grade gliomas. *Current Neurology and Neuroscience Reports*, **2012**, 12, 111-3 | 6.6 | 1 |
| 37 | Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children. *Current Neurology and Neuroscience Reports*, **2009**, 9, 94-6 | 6.6 | 1 |
| 36 | Gene expression profiling to analyze embryonal tumors of the central nervous system. *Current Neurology and Neuroscience Reports*, **2003**, 3, 117-9 | 6.6 | 1 |

| | | | |
|---|---|---|---|
| 35 | Health and functional status of long-term adult medulloblastoma/PNet survivors: A report from the Childhood Cancer Survivor Study.. *Journal of Clinical Oncology*, **2014**, 32, 9515-9515 | 2.2 | 1 |
| 34 | Tumors of the Brain and Spine **2012**, 1339-1387 | | 1 |
| 33 | A phase I trial of lenalidomide and radiotherapy in children with diffuse intrinsic pontine gliomas or high-grade gliomas. *Journal of Neuro-Oncology*, **2020**, 149, 437-445 | 4.8 | 1 |
| 32 | Integrated analysis of pediatric low-grade glioma: clinical implications and the path forward. *Neuro-Oncology*, **2020**, 22, 1413-1414 | 1 | 1 |
| 31 | New treatment modalities in NF-related neuroglial tumors. *Childs Nervous System*, **2020**, 36, 2377-2384 | 1.7 | 1 |
| 30 | Characteristics of Patients 10 Years of Age with Diffuse Intrinsic Pontine Glioma: A Report from the International DIPG Registry. *Neuro-Oncology*, **2021**, | 1 | 1 |
| 29 | Multi-institutional analysis of treatment modalities in basal ganglia and thalamic germinoma. *Pediatric Blood and Cancer*, **2021**, 68, e29172 | 3 | 1 |
| 28 | Anaplastic Ependymoma in a Child With Sickle Cell Anemia: A Case Report Highlighting Treatment Challenges for Young Children With Central Nervous System Tumors and Underlying Vasculopathy. *Pediatric Blood and Cancer*, **2016**, 63, 547-50 | 3 | 1 |
| 27 | DIPG-69. CHARACTERISTICS OF PATIENTS 10 YEARS OF AGE WITH DIFFUSE INTRINSIC PONTINE GLIOMA: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. *Neuro-Oncology*, **2018**, 20, i63-i63 | 1 | 1 |
| 26 | DIPG-51. BLACKFYNN: A SECURE, CLOUD-BASED PLATFORM FOR SHARING AND ANALYZING RESEARCH READY DATA FOR PEDIATRIC CNS CANCERS. *Neuro-Oncology*, **2018**, 20, i59-i59 | 1 | 1 |
| 25 | Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1. *Neurology: Genetics*, **2021**, 7, e616 | 3.8 | 1 |
| 24 | The experience of successful treatment of -positive infant glioblastoma with entrectinib. *Neuro-Oncology Advances*, **2021**, 3, vdab022 | 0.9 | 1 |
| 23 | Center for Neuroscience and Behavioral Medicine: an innovative administrative structure and possible paradigm for the future. *Pediatric Neurology*, **2011**, 44, 1-9 | 2.9 | 0 |
| 22 | MBCL-16. EFFICACY OF CARBOPLATIN GIVEN CONCOMITANTLY WITH RADIATION AND ISOTRETINOIN AS A PRO-APOPTOTIC AGENT IN MAINTENANCE THERAPY IN HIGH-RISK MEDULLOBLASTOMA: A REPORT FROM THE CHILDRENS ONCOLOGY GROUP. *Neuro-Oncology*, **2020**, 22, iii394-iii394 | 1 | 0 |
| 21 | Computerized Working Memory Training for Children With Neurofibromatosis Type 1 (NF1): A Pilot Study. *Journal of Child Neurology*, **2021**, 36, 1078-1085 | 2.5 | 0 |
| 20 | OTHR-08. Pediatric Neurologic Assessment in Neuro-oncology (pNANO) Scale: A tool to assess neurologic function for Response Assessment in Neuro-oncology (RAPNO). *Neuro-Oncology*, **2022**, 24, i148-i148 | 1 | 0 |
| 19 | Parental and physician attitudes toward medulloblastoma treatment. *Pediatric Blood and Cancer*, **2014**, 61, 1149-50 | 3 | |
| 18 | Cingulate Apparent Diffusion Coefficient measurements in children with Neurofibromatosis type 1. *Journal of Pediatric Neuroradiology*, **2015**, 03, 121-126 | | |

| | | |
|---|---|---|
| 17 | Pediatric Brain Tumors (An Overview). *Pediatric Cancer*, **2012**, 61-73 | |
| 16 | Comment: Intracranial ependymomas in children. *Medical and Pediatric Oncology*, **1998**, 30, 330-330 | |
| 15 | Preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma. *Current Neurology and Neuroscience Reports*, **2004**, 4, 127-8 | 6.6 |
| 14 | Journal of Neuro-Oncology: Childhood Brain Tumors. *Journal of Neuro-Oncology*, **2005**, 75, 237-237 | 4.8 |
| 13 | CTNI-10. MAINTENANCE CHEMOTHERAPY USING BEVACIZUMAB FOR NEUROFIBROMATOSIS 2 PATIENTS WITH HEARING LOSS AND PROGRESSIVE VESTIBULAR SCHWANNOMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY (NF104). *Neuro-Oncology*, **2020**, 22, ii43-ii43 | 1 |
| 12 | NIMG-11. VOLUMETRIC ENDPOINTS IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG): COMPARISON TO CROSS-SECTIONAL MEASURES AND CORRELATION WITH OUTCOMES. *Neuro-Oncology*, **2021**, 23, vi129-vi130 | 1 |
| 11 | The Effectiveness of Chemotherapy for Childhood Medulloblastoma (Topics of Malignant Brain Tumors). *Japanese Journal of Neurosurgery*, **1997**, 6, 293-298 | 0 |
| 10 | Infantile Brain Tumors167-175 | |
| 9 | Embryonal Tumors157-166 | |
| 8 | General Approach to Radiation Oncology33-43 | |
| 7 | Event-Free Survival of Children with Average-Risk Medulloblastoma: Treatment with Craniospinal Radiation Followed by Adjuvant Chemotherapy. *Pediatric Cancer*, **2013**, 93-101 | |
| 6 | Chemotherapy for Medulloblastoma□hildhood **2018**, 569-583 | |
| 5 | Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy. *Current Neurology and Neuroscience Reports*, **2007**, 7, 129, 132 | 6.6 |
| 4 | DIPG-48. MRI volumetric and machine learning based analyses predict survival outcome in pediatric diffuse midline glioma. *Neuro-Oncology*, **2022**, 24, i29-i29 | 1 |
| 3 | IMMU-19. Outcomes of Pediatric Patients with High-Risk CNS Tumors Treated with Multi-tumor associated antigen specific T cell (TAA-T) therapy: the ReMIND trial. *Neuro-Oncology*, **2022**, 24, i85-i86 | 1 |
| 2 | IMG-08. Response assessment for pediatric craniopharyngioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. *Neuro-Oncology*, **2022**, 24, i78-i78 | 1 |
| 1 | DIPG-47. TSO500ctDNA sequencing reveals oncogenic mutations and copy number variations in the liquid biome of children with diffuse midline glioma. *Neuro-Oncology*, **2022**, 24, i29-i29 | 1 |